I'm sorry, but it seems like the content you provided is a legal document related to a merger agreement. It does not contain specific financial metrics or changes in financial performance. If you could provide financial data or specific metrics related to the companies involved, I would be happy to help craft a news article based on that information. As a result of these announcements, the company's shares have moved 26.5% on the market, and are now trading at a price of $5.95. Check out the company's full 8-K submission here.
Revance Therapeutics (RVNC) Shares Surge 26.5%
By
Bobby Samwell
• Monday, October 28 10:20 •
Permanent Link
The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.
IN FOCUS
